Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J
PharmaVoice
Pharmaceutical Manufacturing
Washington, District of Columbia 11,913 followers
Covering everything from Molecule to Market
About us
PharmaVoice is for life-sciences executives and other healthcare-service related professionals. The primary audience is made up of executive and corporate management from pharmaceutical, biotechnology, drug delivery, marketing communications, clinical services, contract research, drug development, and information technology companies, as well as other industry sectors. Additionally, PharmaVoice.com has readers from around the world. Subscribe to the daily newsletter at https://dive.pub/3ruPmUL
- Website
-
http://www.pharmavoice.com
External link for PharmaVoice
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Washington, District of Columbia
- Type
- Privately Held
- Specialties
- pharmaceutical, biotechnology, medical devices, life sciences, advertising, marketing, publishing, digital media, editorial, content generation, digital marketing, and marketing strategy
Locations
-
Primary
1100 15th St NW
4th Floor - (Suite 178)
Washington, District of Columbia 20005, US
Employees at PharmaVoice
Updates
-
Cassava Sciences has faced a barrage of regulator scrutiny over alleged clinical impropriety in studies of an experimental #Alzheimer’s candidate. Now, some experts want Cassava to get more heat from the FDA and have its clinical programs ground to a halt. “There is a moral obligation not to experiment on patients in this context," says Dr. Matthew Schrag, Vascular neurologist, assistant professor of neurology, Vanderbilt University. #CassavaSciences Security Exchange Commission https://lnkd.in/ekhSyzd8
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
pharmavoice.com
-
As respiratory disease season approaches, experts are concerned about vaccination rates — but the industry is churning out new solutions to help, like AstraZeneca's at-home flu vaccine #FluMist. #fluseason #pharma https://lnkd.in/eag6gXef
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
pharmavoice.com
-
President and CEO of Biocom California, Joe Panetta, discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future. "The culture of California has always been forward thinking, ahead of the curve," he says. #biotech #California https://lnkd.in/ewMXuYZC
California is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
pharmavoice.com
-
Roivant Sciences CEO Matthew Gline knows where Roivant fits in the bigger biotech and pharma picture, and the hub-and-spoke company has pulled off some major deals in the last few years. How did they stay vibrant during a rough biotech period? In this PharmaVoice interview, Gline provides some perspective.
Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
pharmavoice.com
-
The new CEO of the Cancer Research Institute, Alicia Zhou, PhD wants to leap into the future of oncology drug development through a focus on data-driven research and multidisciplinary perspectives. Read more at PharmaVoice
Want better cancer treatments? Make biopharma more like Silicon Valley
pharmavoice.com
-
Some of the most widely used CROs and CDMOs among US #pharma and biotech companies are based in China. But the industry may soon be forced to cut ties with partners such as WuXi Biologics and WuXi AppTec after the Biosecure Act passed in the House last week. Sound Pharmaceuticals, Inc. Jonathan Kil Citeline #biotech #biosecureact https://lnkd.in/g9Z7TAeN
Biopharma prepares to pivot from China as Biosecure Act advances
pharmavoice.com
-
Treatments for #glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts. “In recent years, immunotherapy has been hailed as the hero for many hard-to-treat oncology indications providing patients with improved prognoses, and it looks as though it could also be the future in glioblastoma treatment,” says Citeline's Flora Mackay. https://lnkd.in/gssJav9e
The hunt for game-changers against the deadliest form of brain cancer
pharmavoice.com
-
Candid Therapeutics, Arsenal Biosciences, Inc. and Formation Bio have managed to close large funding rounds this year while investors are sour on some therapeutic areas. Here's what their funding rounds reveal about the tight market. #biotech https://lnkd.in/emQPfBTr
Who’s winning in biotech’s tight market?
pharmavoice.com
-
From Madrigal Pharmaceuticals’ first ever #MASH drug #Rezdiffra to Eli Lilly and Company’s Alzheimer’s treatment #Kisunla, 2024 has already hosted some big drug approvals. But the year isn’t over, and some of the new drugs heading to market promise significant milestones for prominent diseases. Here are 3 big FDA approval dates to watch in the final months of the year: Bristol Myers Squibb's #KarXT Regeneron and Sanofi's #Dupixent COPD expansion BridgeBio's #acoramidis https://lnkd.in/ewE3rc9X
3 FDA approval dates to watch in the year’s final push
pharmavoice.com